Glenmark receives US FDA approval to expand RYALTRIS nasal spray for children 6‑11 years

What Glenmark announced

Glenmark Pharmaceuticals Ltd filed a Regulation 30 press release on 21 July 2026 stating that the US Food and Drug Administration (FDA) has granted an expanded indication for its RYALTRIS® nasal spray. The product, a fixed‑dose combination of olopatadine hydrochloride and mometasone furoate (665 µg/25 µg per spray), is now approved for the treatment of seasonal allergic rhinitis (SAR) in children aged 6 years up to, but not including, 12 years.

"This approval marks an important step in expanding access to RYALTRIS® in the United States by extending its use to children aged 6 to less than 12 years with Seasonal Allergic Rhinitis," said Marc Kikuchi, President & Business Head, North America.

The announcement also highlighted Glenmark’s transition to direct commercialization of RYALTRIS® in the United States, effective 1 April 2026, giving the company full control over brand strategy, market access, distribution and customer engagement.

Details of FDA approval

The FDA decision expands the existing indication, which covered adults and patients aged 12 years and older, to include a younger pediatric cohort. The approved dosage and formulation remain unchanged – 665 µg of olopatadine and 25 µg of mometasone per spray – but the label now reflects the new age bracket.

Key regulatory points mentioned in the filing:

• Approval is specific to the treatment of SAR symptoms; the product is not indicated for other allergic conditions.
• Safety information includes contraindications for hypersensitivity to any ingredient and warnings for epistaxis, nasal ulcerations, septal perforations, impaired wound healing and Candida infection.
• Somnolence is listed as a precaution; patients are advised to avoid hazardous occupations and concurrent CNS depressants.

Clinical study supporting approval

The FDA’s expanded indication was underpinned by a Phase 3, randomized, double‑blind, placebo‑controlled trial conducted in the United States. The study enrolled 446 children aged 6‑11 years diagnosed with SAR. Over a 14‑day treatment period, participants receiving RYALTRIS® showed statistically significant improvement in nasal symptom scores compared with placebo, and the safety profile was comparable across groups.

The filing cites epidemiological data from the US Centers for Disease Control and Prevention indicating that 25 % of children aged 6‑11 years had a diagnosed seasonal allergy in 2024. By addressing this sizable pediatric market, Glenmark aims to strengthen its respiratory franchise in the US specialty market.

Key facts at a glance

Why this matters for investors

The approval does not involve any immediate capital transaction, but it carries strategic significance:

• Portfolio diversification – Adding a pediatric indication broadens the addressable market for RYALTRIS® and reduces reliance on adult sales.
• Direct commercialization – By owning the end‑to‑end supply chain in the US, Glenmark can capture higher margins and gain richer market intelligence.
• Geographic expansion – The product already enjoys approvals in the EU, UK, Australia, South Korea, Russia and China, and FY26 saw launches in 11 new markets, bringing the total footprint to 56 countries. The US pediatric label further cements its global reach.
• Regulatory credibility – FDA endorsement of a pediatric study may facilitate future submissions for additional indications or dosage forms.
• Revenue outlook – While the filing does not disclose projected sales, the pediatric SAR market represents a sizable segment, given the 25 % prevalence among US school‑age children.

Investors should monitor subsequent updates on market launch timelines, pricing strategy in the US, and any post‑marketing study commitments that may affect future cash flows.

Conclusion

Glenmark’s RYALTRIS® nasal spray has secured US FDA approval for children aged 6 to less than 12 years, expanding its therapeutic scope and reinforcing the company’s direct‑to‑market model in the United States. The decision is backed by a robust Phase 3 pediatric trial and aligns with Glenmark’s broader strategy of growing its respiratory franchise worldwide. No further regulatory approvals are required for the new indication, but commercial rollout details and sales performance will determine the material impact on the company’s financials.